Back to top
more

Abeona Therapeutics (ABEO)

(Real Time Quote from BATS)

$5.84 USD

5.84
6,985

+0.04 (0.69%)

Updated Sep 20, 2024 09:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ChromaDex (CDXC) Jumps: Stock Rises 7.7%

by Zacks Equity Research

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Abeona's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.

Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher

by Zacks Equity Research

Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Aravive (ARAV) in Focus: Stock Moves 8% Higher

by Zacks Equity Research

Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study

by Zacks Equity Research

Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.

Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue

by Zacks Equity Research

Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.

Is Abeona Therapeutics (ABEO) Stock a Solid Choice Right Now?

by Zacks Equity Research

Abeona Therapeutics (ABEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Abeona Therapeutics (ABEO) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Abeona Therapeutics (ABEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Abeona Treats First Patient in Pivotal Gene Therapy Study

by Zacks Equity Research

Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.

Is Earthstone (ESTE) Likely to Beat Q4 Earnings Estimates?

by Zacks Equity Research

Earthstone Energy's (ESTE) fourth-quarter earnings are likely to have been aided by higher oil production.

Factors to Know Ahead of Talos Energy's (TALO) Q4 Earnings

by Zacks Equity Research

Talos Energy's (TALO) fourth-quarter earnings are expected to have taken a hit from lower realized commodity prices.

The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis

Is the Options Market Predicting a Spike in Abeona (ABEO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.

Tirthankar Chakraborty headshot

US Dollar Flexes Muscles Against Other Currencies: 5 Winners

by Tirthankar Chakraborty

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics

Tirthankar Chakraborty headshot

Coronavirus to Hit Apple Sales: Invest in Domestic Producers

by Tirthankar Chakraborty

With the coronavirus threat increasing, it's quite evident that companies having significant exposure to China and the global economy are vulnerable. However, domestic producers of goods should remain unaffected.

Will Abeona Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.

Are Options Traders Betting On A Big Move In Abeona Therapeutics (ABEO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

Abeona Therapeutics (ABEO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -25.64% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Abeona Therapeutics (ABEO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

by Zacks Equity Research

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Earnings Preview: Abeona Therapeutics (ABEO) Q1 Earnings Expected to Decline

by Zacks Equity Research

Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher

by Zacks Equity Research

Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.